1085P Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors

作者：Elizabeth M. Burton, Ecaterina E. Dumbrava, Weiyi Peng, Denái R. Milton, Rodabe N. Amaria, Jennifer L. McQuade, Isabella C. Glitza, David S. Hong, Sapna P. Patel, Jordi Rodón, T.A. Yap, Aung Naing, Sarina A. Piha‐Paul, Gener Balmes, Alexander J. Lazar, Funda Meric‐Bernstam, Patrick Hwu, Michael A. Davies, Hussein A. Tawbi · 发表于：Annals of Oncology · 年份：2021 · DOI：10.1016/j.annonc.2021.08.1470 · 被引用次数：4 · 研究领域：PI3K/AKT/mTOR signaling in cancer、Cancer Immunotherapy and Biomarkers、Melanoma and MAPK Pathways